Lycenol Plus Capsule SR is a sustained-release formulation combining Propranolol 40 mg and Flunarizine 10 mg, designed for the management of migraine prophylaxis and certain cardiovascular conditions. Propranolol, a non-selective beta-adrenergic receptor blocker, exerts its therapeutic effects by reducing heart rate, myocardial contractility, and blood pressure, thereby decreasing cardiac workload and oxygen demand. It is widely utilized in the prevention of angina pectoris, hypertension, and arrhythmias. Flunarizine, a calcium channel blocker with antihistaminic properties, acts by inhibiting the influx of calcium ions into vascular smooth muscle and neuronal cells, contributing to cerebral vasodilation and stabilization of neuronal excitability. This dual-action combination targets both vascular and neurological components implicated in migraine pathophysiology, enhancing prophylactic efficacy. Lycenol Plus Capsule SR’s sustained-release mechanism ensures a gradual and prolonged drug release, improving patient compliance and maintaining steady plasma concentrations. It is contraindicated in patients with bronchial asthma, severe bradycardia, or hypersensitivity to either component. Caution is advised in patients with hepatic or renal impairment. Common adverse effects may include fatigue, dizziness, gastrointestinal disturbances, and potential mood changes. Lycenol Plus Capsule SR should be prescribed under medical supervision with regular monitoring for optimal therapeutic outcomes.